Welcome to our dedicated page for Nano-X Imaging Ltd. SEC filings (Ticker: NNOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NANO-X IMAGING LTD (Nanox) SEC filings page for ticker NNOX provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ. Nanox files an annual report on Form 20-F and furnishes current reports on Form 6-K that cover topics such as capital raises, financial results, shareholder meetings, and significant business developments related to its medical imaging and AI platform.
Recent Form 6-K filings describe a registered direct offering of ordinary shares under an effective shelf registration statement on Form F-3, including the related placement agency agreement, purchase agreement, and legal opinions. Other 6-K reports furnish press releases announcing quarterly financial results, non-GAAP financial measures reconciled to GAAP, and notices and proxy materials for the company’s annual general meeting of shareholders. These documents allow investors to review how Nanox funds its operations and how it reports performance across its Nanox.ARC, radiology services, and AI solutions divisions.
Through this page, users can also track filings that reference Nanox’s imaging systems and AI solutions, including disclosures about commercialization activities, acquisitions such as VasoHealthcare IT, and integration of AI software with health IT infrastructure. The exhibits to these filings may include agreements, opinions, and other materials that provide additional context on Nanox’s operations and capital structure.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand items such as registered offerings, financial updates, or meeting notices. Real-time updates from EDGAR ensure that new 6-Ks, 20-Fs, and related registration statements appear promptly, while dedicated sections highlight ownership and insider-related filings when available. This combination of original SEC documents and AI-generated insights helps investors and researchers analyze NNOX regulatory information more efficiently.
Nano-X Imaging Ltd files Amendment No. 1 to its Form F-3 registration statement to furnish the form of indenture as Exhibit 4.7 and an updated consent of its independent auditors. The prospectus in Part I is unchanged. The registration contemplates sales "from time to time after the effective date".
The filing also restates corporate governance provisions under Israeli law: the company’s articles permit exculpation, indemnification and officers’ insurance to the fullest extent allowed, and indemnification caps include $50 million, 25% of shareholders’ equity, or aggregate offering proceeds, as described. The amendment is signed by the CEO and authorized U.S. agent on March 26, 2026.
Nano-X Imaging Ltd. CFO Daniel Ran reported a disposition of ordinary shares back to the company. On March 18, 2026, he transferred 39,474 ordinary shares to the issuer at a stated price of $0.00 per share. After this issuer-related disposition, he directly holds 46,424 ordinary shares, according to the filing.
Nano-X Imaging Ltd. director Ronen Nehama filed an initial ownership report showing his equity position in the company. The filing lists a stock option to buy 50,000 ordinary shares at an exercise price of $17.63 per share, expiring on December 31, 2033, alongside direct holdings of ordinary shares, including shares underlying restricted share units that vest in twelve equal monthly installments from a December 10, 2025 grant.
Nano-X Imaging Ltd. director Kainan Noga filed an initial ownership report showing a mix of ordinary shares, restricted share units and stock options in the company. One block of ordinary shares consists of restricted share units granted on December 10, 2025 that vest in twelve equal monthly installments over one year.
Noga also holds stock options over 12,505, 50,000 and 10,000 ordinary shares with exercise prices of $64.6100, $17.6300 and $11.5200, expiring in 2031, 2032 and 2033, respectively. Some ordinary shares are held indirectly through I.B.L. Business Consulting Ltd., which is wholly owned by Noga.
Nano-X Imaging Ltd. disclosed the initial holdings of Chief Executive Officer Erez Meltzer. He directly holds 60,584 ordinary shares. He also holds stock options over 40,234 ordinary shares at an exercise price of $2.2100 per share expiring on February 11, 2030, and options over 300,000 ordinary shares at $23.8400 per share expiring on January 2, 2032, both fully vested and exercisable. Additional options over 150,000 ordinary shares at $11.5200 per share expire on April 16, 2034 and vest over four years, with 25% vested after one year and 6.25% vesting quarterly until April 16, 2028.
Nano-X Imaging Ltd. executive Dara James, GM of the Source & Services Division, filed an initial ownership report showing equity-based compensation. James holds stock options over 100,000 ordinary shares at an exercise price of $49.68 expiring on January 18, 2031, plus options over 25,000 and 10,000 shares at $17.63 expiring in 2032, and 55,000 shares at $11.52 expiring in 2033. The filing also reports 39,474 ordinary shares consisting of restricted share units granted on February 5, 2026, with half vesting after 12 months and the rest after 24 months.
Nano-X Imaging Ltd. Chief Legal Officer Marina Gofman Feler filed an initial ownership report on 2026-03-18. She holds stock options over 15,000 ordinary shares at an exercise price of 17.6300 expiring on 2032-11-07, options over 10,000 shares at 17.6300 expiring on 2033-04-28, and options over 30,000 shares at 11.5200 expiring on 2033-05-23.
She also holds 20,000 ordinary shares underlying restricted share units granted on 2026-02-05, which vest 50% on the 12-month anniversary of the grant date and 50% on the 24-month anniversary. A separate line shows 26,316 additional ordinary shares held directly.
Nano-X Imaging Ltd. director Michael Jackman filed an initial ownership report showing his existing equity stake in the company. He holds stock options covering 19,624 ordinary shares at an exercise price of $2.2100 per share, expiring on November 25, 2029, which are fully vested and exercisable. He also reports direct ownership of ordinary shares, including shares underlying restricted share units granted on December 10, 2025 that vest in twelve equal monthly installments over one year.
Nano-X Imaging Ltd. executive Ofir Koren, General Manager of the ARC Division, filed an initial ownership report showing direct holdings of ordinary shares and stock options. The filing lists stock options over 100,000, 25,000 and 33,500 ordinary shares with exercise prices of $49.6800, $17.6300 and $11.5200, expiring between 2031 and 2033. It also describes restricted share units granted in April 2024 and February 2026, which vest over time in scheduled installments.
Nano-X Imaging Ltd. executive Aharon Cohen Tamar, EVP & Chief Marketing Officer, reported his initial equity holdings. He directly holds ordinary shares, including 39,474 ordinary shares, and has 20,000 ordinary shares tied to restricted share units granted on February 5, 2026, which vest 50% after 12 months and 50% after 24 months.
He also holds stock options over ordinary shares: 33,000 at an exercise price of $49.68 expiring on January 18, 2031, 17,000 at $17.63 expiring on March 28, 2032, 8,000 at $17.63 expiring on May 16, 2032, and 55,000 at $11.52 expiring on May 23, 2033. The 2021 grant is fully vested, while the 2022 and 2023 grants vest in 16 equal quarterly installments.